These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 30266801)
1. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801 [TBL] [Abstract][Full Text] [Related]
2. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators. Vachtenheim J; Sestáková B; Tuhácková Z Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875 [TBL] [Abstract][Full Text] [Related]
5. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300. Brown AD; Lynch K; Langelaan DN Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231 [TBL] [Abstract][Full Text] [Related]
6. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525 [TBL] [Abstract][Full Text] [Related]
7. BPTF transduces MITF-driven prosurvival signals in melanoma cells. Dar AA; Majid S; Bezrookove V; Phan B; Ursu S; Nosrati M; De Semir D; Sagebiel RW; Miller JR; Debs R; Cleaver JE; Kashani-Sabet M Proc Natl Acad Sci U S A; 2016 May; 113(22):6254-8. PubMed ID: 27185926 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Bandyopadhyay D; Okan NA; Bales E; Nascimento L; Cole PA; Medrano EE Cancer Res; 2002 Nov; 62(21):6231-9. PubMed ID: 12414652 [TBL] [Abstract][Full Text] [Related]
9. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925 [TBL] [Abstract][Full Text] [Related]
10. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. Martire S; Nguyen J; Sundaresan A; Banaszynski LA BMC Mol Cell Biol; 2020 Jul; 21(1):55. PubMed ID: 32690000 [TBL] [Abstract][Full Text] [Related]
11. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Saladi SV; Wong PG; Trivedi AR; Marathe HG; Keenen B; Aras S; Liew ZQ; Setaluri V; de la Serna IL Pigment Cell Melanoma Res; 2013 May; 26(3):377-91. PubMed ID: 23480510 [TBL] [Abstract][Full Text] [Related]
12. Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor. Brown AD; Vergunst KL; Branch M; Blair CM; Dupré DJ; Baillie GS; Langelaan DN Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119520. PubMed ID: 37353163 [TBL] [Abstract][Full Text] [Related]